Endoscape, Inc. - Product Pipeline Analysis

Endoscape, Inc. - Product Pipeline Analysis

Endoscape, Inc. (Endoscape) is a pharmaceutical company. The company plans to bring colonoscopy, the Gold Standard of colon cancer screening, to people through the development of novel products and services for a milder colon preparation and colonoscopy procedure. Endoscape carries out a methodical search for the development of Insertion Accessory Devices, which is a simple and low cost solution for solving the technical difficulties of a deep colon intubation. It also develops transformational device technologies for the hand laparoscopic surgery. The company is headquartered in California, the US.

This report is a source for data, analysis and actionable intelligence on the Endoscape, Inc. portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the development stage, trial phase, product milestones, pipeline territory, estimated approval date, and estimated launch date

Each pipeline product is profiled to cover information on product description, function, technology, indication, and application. The report is also supplemented with a detailed company profile and information on clinical trials, wherever applicable.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Scope

• Detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments.
• Detailed coverage on all the pipeline products, by equipment type, by therapy area, by development stage, and by trial phase.
• Information on product milestones and pipeline territory for each product, the estimated approval date, and estimated launch date.
• Profile of each pipeline product with additional information on product description, function, technology, indication(s), and application.
• Data on relevant clinical trials and product patent details, wherever applicable.
• Information on clinical trial, wherever applicable, is supplemented with information on trial phase, trial status, trial objective, trial design, target patients, unique physician identifier, primary point, secondary point, acronym, participants inclusion, participants exclusion, interventions, trial results, trial start date, trial end date, study type, trial site, trial funding, age eligibility, and gender eligibility.

Reasons to Buy

• Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape globally.
• Design and develop your product development, marketing and sales strategies.
• Exploit M&A opportunities by identifying market players with the most innovative pipeline.
• Develop market-entry and market expansion strategies.
• Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return.
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Develop competition strategies by identifying the status and likely launch of your competitors' pipeline products through review of the clinical trials, stage and phase of development, etc.Which are the next high-value products that your competitor would add in its portfolio? identify, understand and capitalize.

Visit:  http://www.marketresearchreports.com

InVivo Therapeutics Corporation - Product Pipeline Analysis

InVivo Therapeutics Corporation - Product Pipeline Analysis

InVivo Therapeutics Corporation(InVivo) is a medical device company. InVivo is a subsidiary of InVivo Therapeutics Holdings Corp. Its products seek to protect the spinal cord after primary injury by mitigating the bleeding, inflammation, and further cell death that result from the body's immune response to spinal cord injuries(SCI). It develops and commercializes biocompatible polymer scaffolding devices for the treatment of acute SCI. The biocompatible polymer devices are fabricated to protect the damaged spinal cord from further secondary injury and promote neuroplasticity. It also offers biocompatible hydrogel for local controlled release of methylprednisolone to treat acute SCI and biocompatible polymer scaffolding device seeded with autologous hNSCs to treat acute and chronic SCI. InVivo is headquartered in Cambridge,Massachusetts, the US.

This report is a source for data, analysis and actionable intelligence on the InVivo Therapeutics Corporation portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the development stage, trial phase, product milestones, pipeline territory, estimated approval date, and estimated launch date

Each pipeline product is profiled to cover information on product description, function, technology, indication, and application. The report is also supplemented with a detailed company profile and information on clinical trials, wherever applicable.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Scope

• Detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments.
• Detailed coverage on all the pipeline products, by equipment type, by therapy area, by development stage, and by trial phase.
• Information on product milestones and pipeline territory for each product, the estimated approval date, and estimated launch date.
• Profile of each pipeline product with additional information on product description, function, technology, indication(s), and application.
• Data on relevant clinical trials and product patent details, wherever applicable.
• Information on clinical trial, wherever applicable, is supplemented with information on trial phase, trial status, trial objective, trial design, target patients, unique physician identifier, primary point, secondary point, acronym, participants inclusion, participants exclusion, interventions, trial results, trial start date, trial end date, study type, trial site, trial funding, age eligibility, and gender eligibility.

Reasons to Buy

• Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape globally.
• Design and develop your product development, marketing and sales strategies.
• Exploit M&A opportunities by identifying market players with the most innovative pipeline.
• Develop market-entry and market expansion strategies.
• Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return.
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Develop competition strategies by identifying the status and likely launch of your competitors' pipeline products through review of the clinical trials, stage and phase of development, etc.Which are the next high-value products that your competitor would add in its portfolio? identify, understand and capitalize.

Visit:  http://www.marketresearchreports.com

BioSET, Inc - Product Pipeline Analysis

BioSET, Inc - Product Pipeline Analysis

BioSET, Inc (BioSET) is a medical equipment as well as drug manufacturer company. The company has expertise in developing orthobiologic devices. Its products are next-generation combination devices that couples with bioactive peptides with tissue-specific scaffolds. Its main product is AMPLEX device which is a combination of the B2A peptide and a synthetic ceramic scaffold with chemical properties similar to that of native bone. AMPLEX is currently under investigation in human clinical trials as a surgical bone graft implant for lumbar degenerative disc disease. BioSET also forms collaboration with Tornier, Inc. for the development of products for sports medicine applications. It also intends to develop products for use in musculoskeletal applications such as trauma, fracture repair and additional soft tissue treatments. The company is headquartered at Rockville, Maryland, the US.

This report is a source for data, analysis and actionable intelligence on the BioSET, Inc portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the development stage, trial phase, product milestones, pipeline territory, estimated approval date, and estimated launch date

Each pipeline product is profiled to cover information on product description, function, technology, indication, and application. The report is also supplemented with a detailed company profile and information on clinical trials, wherever applicable.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Scope

• Detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments.
• Detailed coverage on all the pipeline products, by equipment type, by therapy area, by development stage, and by trial phase.
• Information on product milestones and pipeline territory for each product, the estimated approval date, and estimated launch date.
• Profile of each pipeline product with additional information on product description, function, technology, indication(s), and application.
• Data on relevant clinical trials and product patent details, wherever applicable.
• Information on clinical trial, wherever applicable, is supplemented with information on trial phase, trial status, trial objective, trial design, target patients, unique physician identifier, primary point, secondary point, acronym, participants inclusion, participants exclusion, interventions, trial results, trial start date, trial end date, study type, trial site, trial funding, age eligibility, and gender eligibility.

Reasons to Buy

• Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape globally.
• Design and develop your product development, marketing and sales strategies.
• Exploit M&A opportunities by identifying market players with the most innovative pipeline.
• Develop market-entry and market expansion strategies.
• Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return.
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Develop competition strategies by identifying the status and likely launch of your competitors' pipeline products through review of the clinical trials, stage and phase of development, etc.Which are the next high-value products that your competitor would add in its portfolio? identify, understand and capitalize.

Visit:  http://www.marketresearchreports.com

Analyticon Biotechnologies AG - Product Pipeline Analysis

Analyticon Biotechnologies AG - Product Pipeline Analysis

Analyticon Biotechnologies AG (Analyticon) is a global diagnostic corporation. It provides diagnostic solutions to physicians, hospitals and clinical laboratories. The company classifies its product portfolio into four business lines: Urinalysis, Clinical Chemistry, Hematology and Coagulation. Clinical Chemistry undertakes diagnosis of routine clinical chemistry, specific proteins, substrates and enzymes, lipid profile, diabetes,a nd electrolytes. Through Coagulyzer instruments , the company treats coagulation disorders. It also offers customer support to all its partners worldwide. It condicts Hematology testing to diagnose anemia, hemophilia, blood-clotting disorders, and leukemia. Its Combi-Screen PLUS test strip are faster and cost-effective means of testing. The company has production locations and storing facilities in Germany. It markets its products in Europe, the Middle East, Africa, Asia-Pacific and Americas through distributor organizations. Analyticon is headquartered in Lichtenfels, Germany.

This report is a source for data, analysis and actionable intelligence on the Analyticon Biotechnologies AG portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the development stage, trial phase, product milestones, pipeline territory, estimated approval date, and estimated launch date

Each pipeline product is profiled to cover information on product description, function, technology, indication, and application. The report is also supplemented with a detailed company profile and information on clinical trials, wherever applicable.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Scope

• Detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments.
• Detailed coverage on all the pipeline products, by equipment type, by therapy area, by development stage, and by trial phase.
• Information on product milestones and pipeline territory for each product, the estimated approval date, and estimated launch date.
• Profile of each pipeline product with additional information on product description, function, technology, indication(s), and application.
• Data on relevant clinical trials and product patent details, wherever applicable.
• Information on clinical trial, wherever applicable, is supplemented with information on trial phase, trial status, trial objective, trial design, target patients, unique physician identifier, primary point, secondary point, acronym, participants inclusion, participants exclusion, interventions, trial results, trial start date, trial end date, study type, trial site, trial funding, age eligibility, and gender eligibility.

Reasons to Buy

• Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape globally.
• Design and develop your product development, marketing and sales strategies.
• Exploit M&A opportunities by identifying market players with the most innovative pipeline.
• Develop market-entry and market expansion strategies.
• Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return.
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Develop competition strategies by identifying the status and likely launch of your competitors' pipeline products through review of the clinical trials, stage and phase of development, etc.Which are the next high-value products that your competitor would add in its portfolio? identify, understand and capitalize.

Visit:  http://www.marketresearchreports.com

Navotek Medical Ltd. - Product Pipeline Analysis

Navotek Medical Ltd. - Product Pipeline Analysis

Navotek Medical Ltd. (Navotek) is an intra-body tracking technologies developer. The company provides RealEye, a fiducial-based patient positioning and realtime target monitoring system for radiation therapy. It offers realeyeable tracer, an implantable trackable fiducial for use with the patient positioning and monitoring system. Navotek's RealEye Motion is an advanced software application, which enables monitoring and tracking of moving organs paths throughout radiation therapy. It offers Tracer for use in marking target tissue and enabling localization based on its radioactive signal. Navotek is headquartered in Yokneam, Israel.

This report is a source for data, analysis and actionable intelligence on the Navotek Medical Ltd. portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the development stage, trial phase, product milestones, pipeline territory, estimated approval date, and estimated launch date

Each pipeline product is profiled to cover information on product description, function, technology, indication, and application. The report is also supplemented with a detailed company profile and information on clinical trials, wherever applicable.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Scope

• Detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments.
• Detailed coverage on all the pipeline products, by equipment type, by therapy area, by development stage, and by trial phase.
• Information on product milestones and pipeline territory for each product, the estimated approval date, and estimated launch date.
• Profile of each pipeline product with additional information on product description, function, technology, indication(s), and application.
• Data on relevant clinical trials and product patent details, wherever applicable.
• Information on clinical trial, wherever applicable, is supplemented with information on trial phase, trial status, trial objective, trial design, target patients, unique physician identifier, primary point, secondary point, acronym, participants inclusion, participants exclusion, interventions, trial results, trial start date, trial end date, study type, trial site, trial funding, age eligibility, and gender eligibility.

Reasons to Buy

• Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape globally.
• Design and develop your product development, marketing and sales strategies.
• Exploit M&A opportunities by identifying market players with the most innovative pipeline.
• Develop market-entry and market expansion strategies.
• Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return.
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Develop competition strategies by identifying the status and likely launch of your competitors' pipeline products through review of the clinical trials, stage and phase of development, etc.Which are the next high-value products that your competitor would add in its portfolio? identify, understand and capitalize.

Visit:  http://www.marketresearchreports.com

OncoSec Medical Inc. (ONCS) - Product Pipeline Analysis

OncoSec Medical Inc. (ONCS) - Product Pipeline Analysis

OncoSec Medical Inc. (OncoSec), formerly known as Netventory Solutions, Inc., is an emerging drug-medical device and therapeutic company. It provides treatment for advanced-stage skin cancer such as melanoma, Merkel cell lymphoma, and cutaneous T-cell lymphoma. It conducts two kinds of tests to eradicate various kinds of cancers such as ImmunoPulse and NeoPulse. Its ImmunoPulse is used to treat metastatic cancers and NeoPulse is used to treat primary and recurrent cancers that have not yet spread to other parts of the body. Its OncoSec Medical System (OMS) is based on electroporation technology which has the potential to extend lifespan and enhance the quality of life for people whose cancers are resistant to conventional treatment approaches. The company is headquartered in San Diego, California, the US.

This report is a source for data, analysis and actionable intelligence on the OncoSec Medical Inc. portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the development stage, trial phase, product milestones, pipeline territory, estimated approval date, and estimated launch date

Each pipeline product is profiled to cover information on product description, function, technology, indication, and application. The report is also supplemented with a detailed company profile and information on clinical trials, wherever applicable.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Scope

• Detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments.
• Detailed coverage on all the pipeline products, by equipment type, by therapy area, by development stage, and by trial phase.
• Information on product milestones and pipeline territory for each product, the estimated approval date, and estimated launch date.
• Profile of each pipeline product with additional information on product description, function, technology, indication(s), and application.
• Data on relevant clinical trials and product patent details, wherever applicable.
• Information on clinical trial, wherever applicable, is supplemented with information on trial phase, trial status, trial objective, trial design, target patients, unique physician identifier, primary point, secondary point, acronym, participants inclusion, participants exclusion, interventions, trial results, trial start date, trial end date, study type, trial site, trial funding, age eligibility, and gender eligibility.

Reasons to Buy

• Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape globally.
• Design and develop your product development, marketing and sales strategies.
• Exploit M&A opportunities by identifying market players with the most innovative pipeline.
• Develop market-entry and market expansion strategies.
• Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return.
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Develop competition strategies by identifying the status and likely launch of your competitors' pipeline products through review of the clinical trials, stage and phase of development, etc.Which are the next high-value products that your competitor would add in its portfolio? identify, understand and capitalize.

Visit:  http://www.marketresearchreports.com

Taiwan In Vitro Diagnostics Market Outlook to 2018 - Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture

Taiwan In Vitro Diagnostics Market Outlook to 2018

Taiwan In Vitro Diagnostics Market Outlook to 2018 Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture report provides key market data on the Taiwan In Vitro Diagnostics market. The report provides value (USD million), volume (units) and average price (USD) data for each segment and sub-segment within market categories Immuno Chemistry, Infectious Immunology, Clinical Chemistry, Haematology, Microbiology Culture, Histology And Cytology and Genetic Testing. The report also provides company shares and distribution shares data for each of the aforementioned market categories. The report is supplemented with global corporate-level profiles of the key market participants with information on company financials and pipeline products, wherever available.

 

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

 

Scope

• Market size and company share data for In Vitro Diagnostics market categories Immuno Chemistry, Infectious Immunology, Clinical Chemistry, Haematology, Microbiology Culture, Histology And Cytology and Genetic Testing.
• Annualized market revenues (USD million), volume (units) and average price (USD) data for each of the segments and sub-segments within market categories. Data from 2004 to 2011, forecast forward for 7 years to 2018. 
• 2011 company shares and distribution shares data for each of the market categories.
• Global corporate-level profiles of key companies operating within the Taiwan In Vitro Diagnostics market.
• Key players covered include Abbott Laboratories, F. Hoffmann-La Roche Ltd., Sysmex Corporation, Siemens Healthcare, Beckman Coulter, Inc., bioMerieux S.A. and others.

 

Reasons to buy

• Develop business strategies by identifying the key market categories and segments poised for strong growth.
• Develop market-entry and market expansion strategies.
• Design competition strategies by identifying who-stands-where in the Taiwan In Vitro Diagnostics competitive landscape.
• Develop capital investment strategies by identifying the key market segments expected to register strong growth in the near future.
• What are the key distribution channels and what's the most preferred mode of product distribution Identify, understand and capitalize.

To purchase and know more about this market research reports please visit:  http://www.marketresearchreports.com/globaldata/taiwan-vitro-diagnostics-market-outlook-2018-clinical-chemistry-genetic-testing

Netherlands In Vitro Diagnostics Market Outlook to 2018 - Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture

Netherlands In Vitro Diagnostics Market Outlook to 2018

Netherlands In Vitro Diagnostics Market Outlook to 2018 Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture report provides key market data on the Netherlands In Vitro Diagnostics market. The report provides value (USD million), volume (units) and average price (USD) data for each segment and sub-segment within market categories – Immuno Chemistry, Infectious Immunology, Clinical Chemistry, Haematology, Microbiology Culture, Histology And Cytology and Genetic Testing. The report also provides company shares and distribution shares data for each of the aforementioned market categories. The report is supplemented with global corporate-level profiles of the key market participants with information on company financials and pipeline products, wherever available.

 

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

 

Scope

• Market size and company share data for In Vitro Diagnostics market categories – Immuno Chemistry, Infectious Immunology, Clinical Chemistry, Haematology, Microbiology Culture, Histology And Cytology and Genetic Testing.
• Annualized market revenues (USD million), volume (units) and average price (USD) data for each of the segments and sub-segments within market categories. Data from 2004 to 2011, forecast forward for 7 years to 2018. 
• 2011 company shares and distribution shares data for each of the market categories.
• Global corporate-level profiles of key companies operating within the Netherlands In Vitro Diagnostics market.
• Key players covered include F. Hoffmann-La Roche Ltd., Siemens Healthcare, Abbott Laboratories, Beckman Coulter, Inc., Ortho-Clinical Diagnostics Inc., bioMerieux S.A. and others.

 To purchase and know more about this market research reports please visit: http://www.marketresearchreports.com/globaldata/netherlands-vitro-diagnostics-market-outlook-2018-clinical-chemistry-genetic-testing

 

Reasons to buy

• Develop business strategies by identifying the key market categories and segments poised for strong growth.
• Develop market-entry and market expansion strategies.
• Design competition strategies by identifying who-stands-where in the Netherlands In Vitro Diagnostics competitive landscape.
• Develop capital investment strategies by identifying the key market segments expected to register strong growth in the near future.
• What are the key distribution channels and what’s the most preferred mode of product distribution – Identify, understand and capitalize.

France In Vitro Diagnostics Market Outlook to 2018 - Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture

France In Vitro Diagnostics Market Outlook to 2018 

France In Vitro Diagnostics Market Outlook to 2018 Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture report provides key market data on the France In Vitro Diagnostics market. The report provides value (USD million), volume (units) and average price (USD) data for each segment and sub-segment within market categories – Immuno Chemistry, Clinical Chemistry, Haematology, Infectious Immunology, Histology And Cytology, Microbiology Culture and Genetic Testing. The report also provides company shares and distribution shares data for each of the aforementioned market categories. The report is supplemented with global corporate-level profiles of the key market participants with information on company financials and pipeline products, wherever available.

To purchase and know more about this market research reports please visit: http://www.marketresearchreports.com/globaldata/france-vitro-diagnostics-market-outlook-2018-clinical-chemistry-genetic-testing 

 

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

 

Scope

• Market size and company share data for In Vitro Diagnostics market categories – Immuno Chemistry, Clinical Chemistry, Haematology, Infectious Immunology, Histology And Cytology, Microbiology Culture and Genetic Testing.
• Annualized market revenues (USD million), volume (units) and average price (USD) data for each of the segments and sub-segments within market categories. Data from 2004 to 2011, forecast forward for 7 years to 2018. 
• 2011 company shares and distribution shares data for each of the market categories.
• Global corporate-level profiles of key companies operating within the France In Vitro Diagnostics market.
• Key players covered include F. Hoffmann-La Roche Ltd., Siemens Healthcare, Abbott Laboratories, Beckman Coulter, Inc., bioMerieux S.A., Ortho-Clinical Diagnostics Inc.and others.

 

Reasons to buy

• Develop business strategies by identifying the key market categories and segments poised for strong growth.
• Develop market-entry and market expansion strategies.
• Design competition strategies by identifying who-stands-where in the France In Vitro Diagnostics competitive landscape.
• Develop capital investment strategies by identifying the key market segments expected to register strong growth in the near future.
• What are the key distribution channels and what’s the most preferred mode of product distribution – Identify, understand and capitalize.

Germany In Vitro Diagnostics Market Outlook to 2018 - Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture

Germany In Vitro Diagnostics Market Outlook to 2018

Germany In Vitro Diagnostics Market Outlook to 2018 Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture report provides key market data on the Germany In Vitro Diagnostics market. The report provides value (USD million), volume (units) and average price (USD) data for each segment and sub-segment within market categories – Immuno Chemistry, Clinical Chemistry, Haematology, Infectious Immunology, Histology And Cytology, Microbiology Culture and Genetic Testing. The report also provides company shares and distribution shares data for each of the aforementioned market categories. The report is supplemented with global corporate-level profiles of the key market participants with information on company financials and pipeline products, wherever available.

 

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

 

Scope

• Market size and company share data for In Vitro Diagnostics market categories – Immuno Chemistry, Clinical Chemistry, Haematology, Infectious Immunology, Histology And Cytology, Microbiology Culture and Genetic Testing.
• Annualized market revenues (USD million), volume (units) and average price (USD) data for each of the segments and sub-segments within market categories. Data from 2004 to 2011, forecast forward for 7 years to 2018. 
• 2011 company shares and distribution shares data for each of the market categories.
• Global corporate-level profiles of key companies operating within the Germany In Vitro Diagnostics market.
• Key players covered include F. Hoffmann-La Roche Ltd., Siemens Healthcare, Abbott Laboratories, Beckman Coulter, Inc., Ortho-Clinical Diagnostics Inc., bioMerieux S.A. and others.

 

Reasons to buy

• Develop business strategies by identifying the key market categories and segments poised for strong growth.
• Develop market-entry and market expansion strategies.
• Design competition strategies by identifying who-stands-where in the Germany In Vitro Diagnostics competitive landscape.
• Develop capital investment strategies by identifying the key market segments expected to register strong growth in the near future.
• What are the key distribution channels and what’s the most preferred mode of product distribution – Identify, understand and capitalize.

To purchase and know more about this market research reports please visit:  http://www.marketresearchreports.com/globaldata/germany-vitro-diagnostics-market-outlook-2018-clinical-chemistry-genetic-testing 

Europe In Vitro Diagnostics Market Outlook to 2018 - Clinical Chemistry, Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture

Europe In Vitro Diagnostics Market Outlook to 2018

Europe In Vitro Diagnostics Market Outlook to 2018 Clinical Chemistry, Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture report provides key market data on the Europe In Vitro Diagnostics Market – Germany, France, Italy, Spain and United Kingdom. The report provides value (USD million) data for all the market categories – Immuno Chemistry, Clinical Chemistry, Haematology, Infectious Immunology, Microbiology Culture, Histology And Cytology and Genetic Testing. The report also provides company shares and distribution shares data for each of the aforementioned market categories. The report is supplemented with global corporate-level profiles of the key market participants.

 

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

To purchase and know more about this market research reports please visit: http://www.marketresearchreports.com/globaldata/europe-vitro-diagnostics-market-outlook-2018-clinical-chemistry-genetic-testing 

 

Scope

• Countries covered include Germany, France, Italy, Spain and United Kingdom. 
• Market size and company share data for In Vitro Diagnostics market categories – Immuno Chemistry, Clinical Chemistry, Haematology, Infectious Immunology, Microbiology Culture, Histology And Cytology and Genetic Testing.
• Annualized market revenues (USD million) data for each of the market categories in each of the country. Data from 2004 to 2011, forecast forward for 7 years to 2018. 
• 2011 company shares and distribution shares data for each of the market categories and countries.
• Global corporate-level profiles of key companies operating within the Europe In Vitro Diagnostics market.
• Key players covered include F. Hoffmann-La Roche Ltd., Siemens Healthcare, Abbott Laboratories, Beckman Coulter, Inc., Ortho-Clinical Diagnostics Inc., bioMerieux S.A., Sysmex Corporation, Bio-Rad Laboratories, Inc., Becton, Dickinson and Company, Alere Inc., DiaSorin S.p.A, Phadia AB and Qiagen N.V.

 

Reasons to buy

• Develop business strategies by identifying the key market categories and segments poised for strong growth.
• Develop market-entry and market expansion strategies.
• Design competition strategies by identifying who-stands-where in the Europe In Vitro Diagnostics competitive landscape.
• Develop capital investment strategies by identifying the key market segments expected to register strong growth in the near future.
• What are the key distribution channels and what’s the most preferred mode of product distribution – Identify, understand and capitalize.

Humira (Rheumatoid Arthritis) Forecast and Market Analysis

Humira (Rheumatoid Arthritis) Forecast and Market Analysis

The RA market is currently very dynamic, with the November 6, 2012 FDA approval of Pfizer's Xeljanz (tofacitinib) and novel oral therapies awaiting approval such as: Eli Lilly's anti-BAFF, tabalumab and JAK1,2 inhibitor, baricitinib, and Rigel/AZ's SYK inhibitor, fostamatinib. These compounds will challenge the current biologics in the attempt to dislodge the stronghold of the TNF inhibitors, if their safety and efficacy profiles are proven once they enter the market. Humira is a recombinant human IgG1 monoclonal antibody (mAb) which binds to TNF-alpha and blocks interaction with p55 and p75 cell-surface receptors; this blockage reduces inflammation and stops tissue destruction. It was the first fully humanized mAb TNF inhibitor to enter the market for the treatment of RA. In 2012, pharmaceutical industry analysts estimate that Humira will be the “world's top-selling medicine” at $9 billion in sales.

To purchase and know more about this market research reports please visit:  http://www.marketresearchreports.com/globaldata/humira-rheumatoid-arthritis-forecast-and-market-analysis

 

Scope

• Overview of RA, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
• Detailed information on Humira including product description, safety and efficacy profiles as well as a SWOT analysis.
• Sales forecast for Humira for the top eight countries from 2011 to 2022.
• Sales information covered for the US, France, Germany, the UK, Italy, Spain, Japan and Australia

 

Reasons to buy

• Understand and capitalize by identifying products that are most likely to ensure a robust return
• Stay ahead of the competition by understanding the changing competitive landscape for rheumatoid arthritis.
• Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
• Make more informed business decisions from insightful and in-depth analysis of Humira performance
• Obtain sales forecast for Humira from 2011 to 2022 in (the US, France, Germany, the UK, Italy, Spain, Japan and Australia)

PharmaPoint: Rheumatoid Arthritis - France Drug Forecast and Market Analysis Event-Driven Update

PharmaPoint: Rheumatoid Arthritis - France Drug Forecast and Market Analysis Event-Driven Update

The RA market is currently very dynamic, with the November 6, 2012 FDA approval of Pfizer's Xeljanz (tofacitinib) and novel oral therapies awaiting approval such as: Eli Lilly's anti-BAFF, tabalumab and JAK1,2 inhibitor, baricitinib, and Rigel/AZ's SYK inhibitor, fostamatinib. These compounds will challenge the current biologics in the attempt to dislodge the stronghold of the TNF inhibitors, if their safety and efficacy profiles are proven once they enter the market.

 

French physicians included in this report may follow guidelines such as ACR, but also follow their own clinical experience to treat RA patients. In France, about 29% of referrals of patients presenting in any stage come from PCPs; however, other specialists including orthopedic surgeons are high referrers as well. Also, most people seeking treatment are 55 years and older. Within this age group, females outnumber the males by a small margin compared with the younger age groups.

To purchase and know more about this market research reports please visit:   http://www.marketresearchreports.com/globaldata/pharmapoint-rheumatoid-arthritis-france-drug-forecast-and-market-analysis-event-driven

Scope

• Overview of RA, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
• Detailed information on the key drugs in the France including product description, safety and efficacy profiles as well as a SWOT analysis.
• Sales forecast for the top drugs in France from 2011 to 2022.
• Analysis of the impact of key events as well the drivers and restraints affecting the France rheumatoid arthritis market.

 

Reasons to buy

• Understand and capitalize by identifying products that are most likely to ensure a robust return
• Stay ahead of the competition by understanding the changing competitive landscape for rheumatoid arthritis
• Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
• Make more informed business decisions from insightful and in-depth analysis of rheumatoid arthritis drug performance in France
• Obtain sales forecast from 2011-2022 in France